Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung02: datopotamab deruxtecan with pembrolizumab with or without platinum chemotherapy in advanced or metastatic non-small cell lung cancer
jRCT2031200193Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of datopotamab deruxtecan, pembrolizumab, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Number of participants with dose-limiting toxicities and treatment-emergent adverse events. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031200193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200193.